Techdow USA, a wholly owned subsidiary of Hepalink USA Inc., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), an integrated company engaged in the Development, Manufacturing and Licensing of pharmaceuticals, announced the signing of a Licensing, Supply, and Distribution agreement regarding the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection in the US market.